S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
15 A.I. Trading Opportunities a Day (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
15 A.I. Trading Opportunities a Day (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
15 A.I. Trading Opportunities a Day (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
15 A.I. Trading Opportunities a Day (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:GRFS

Grifols (GRFS) Stock Forecast, Price & News

$8.80
+0.46 (+5.52%)
(As of 06/2/2023 ET)
Compare
Today's Range
$8.73
$8.96
50-Day Range
$7.05
$9.01
52-Week Range
$5.71
$13.10
Volume
435,104 shs
Average Volume
810,948 shs
Market Capitalization
$6.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.52

Grifols MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
42.3% Upside
$12.52 Price Target
Short Interest
Bearish
2.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
43.90%
From $0.82 to $1.18 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

597th out of 983 stocks

Pharmaceutical Preparations Industry

296th out of 486 stocks


GRFS stock logo

About Grifols (NASDAQ:GRFS) Stock

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Receive GRFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Grifols and its competitors with MarketBeat's FREE daily newsletter.

GRFS Stock News Headlines

15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Grifols SA Pref (GRLSbn)
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Why Shares of Grifols Were Up Tuesday
StockNews.com Lowers Grifols (NASDAQ:GRFS) to Hold
StockNews.com Downgrades Grifols (NASDAQ:GRFS) to Hold
Grifols (NASDAQ:GRFS) Shares Gap Down to $7.53
Grifols (NASDAQ:GRFS) Upgraded by StockNews.com to "Buy"
Grifols (NASDAQ:GRFS) Stock Rating Lowered by StockNews.com
Grifols (NASDAQ:GRFS) Upgraded to Buy by StockNews.com
Grifols (NASDAQ:GRFS) Trading 6.5% Higher
Are Investors Undervaluing Grifols (GRFS) Right Now?
Grifols (GRFS) Upgraded to Strong Buy: Here's Why
Is Grifols (GRFS) Stock Undervalued Right Now?
See More Headlines

GRFS Price History

GRFS Company Calendar

Last Earnings
5/04/2021
Today
6/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GRFS
Employees
26,314
Year Founded
1909

Price Target and Rating

Average Stock Price Forecast
$12.52
High Stock Price Forecast
$20.30
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+42.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.39 billion
Cash Flow
$1.00 per share
Book Value
$12.76 per share

Miscellaneous

Free Float
686,249,000
Market Cap
$6.05 billion
Optionable
Optionable
Beta
0.40

Social Links


Key Executives

  • Thomas Heinrich Glanzmann
    Executive Chairman & Chief Executive Officer
  • Victor Grifols Deu
    Chief Operating Officer & Executive Director
  • Alfredo Arroyo Guerra
    Chief Financial Officer & Vice President
  • Xavier Sueiras Gil
    Chief Information Technology Officer
  • Marilyn Rosa-Bray
    Chief Medical Officer & SVP-Global Plasma Quality













GRFS Stock - Frequently Asked Questions

Should I buy or sell Grifols stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GRFS shares.
View GRFS analyst ratings
or view top-rated stocks.

What is Grifols' stock price forecast for 2023?

7 Wall Street research analysts have issued 1 year price objectives for Grifols' stock. Their GRFS share price forecasts range from $9.00 to $20.30. On average, they expect the company's stock price to reach $12.52 in the next twelve months. This suggests a possible upside of 42.3% from the stock's current price.
View analysts price targets for GRFS
or view top-rated stocks among Wall Street analysts.

How have GRFS shares performed in 2023?

Grifols' stock was trading at $8.50 on January 1st, 2023. Since then, GRFS stock has increased by 3.5% and is now trading at $8.80.
View the best growth stocks for 2023 here
.

How were Grifols' earnings last quarter?

Grifols, S.A. (NASDAQ:GRFS) released its quarterly earnings results on Tuesday, May, 4th. The biotechnology company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.22 by $0.01. The biotechnology company earned $1.43 billion during the quarter.

What ETFs hold Grifols' stock?
When did Grifols' stock split?

Shares of Grifols split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly issued shares were payable to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Raimon Grifols and Victor Grifols Deu's approval rating as Grifols' CEO?

205 employees have rated Grifols Chief Executive Officer Raimon Grifols and Victor Grifols Deu on Glassdoor.com. Raimon Grifols and Victor Grifols Deu has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Grifols own?
What is Grifols' stock symbol?

Grifols trades on the NASDAQ under the ticker symbol "GRFS."

Who are Grifols' major shareholders?

Grifols' stock is owned by many different institutional and retail investors. Top institutional shareholders include Brandes Investment Partners LP (1.50%), Black Creek Investment Management Inc. (1.09%), First Trust Advisors LP (0.81%), Pictet Asset Management SA (0.80%), FIL Ltd (0.67%) and Bank of America Corp DE (0.62%).

How do I buy shares of Grifols?

Shares of GRFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Grifols' stock price today?

One share of GRFS stock can currently be purchased for approximately $8.80.

How much money does Grifols make?

Grifols (NASDAQ:GRFS) has a market capitalization of $6.05 billion and generates $6.39 billion in revenue each year.

How many employees does Grifols have?

The company employs 26,314 workers across the globe.

Does Grifols have any subsidiaries?
The following companies are subsidiares of Grifols: Aigües Minerals de Vilajuiga S.A., Araclon Biotech, Araclon Biotech S.L., Asociación I+D Progenika, Biomat S.A., Biomat USA Inc., Biotest Pharmaceutical Corporation, Biotest US Corporation, Chiquito Acquisition Corp., Diagnostic Grifols S.A., Goetech LLC (D/B/A Medkeeper), Gri-Cel S.A. , Grifols (H.K.) Limited, Grifols (Thailand) Ltd, Grifols Argentina S.A., Grifols Asia Pacific Pte Ltd, Grifols Australia Pty Ltd., Grifols Biologicals LLC., Grifols Brasil Lda., Grifols Canada Ltd., Grifols Chile S.A., Grifols Colombia Ltda, Grifols Deutschland GmbH, Grifols Diagnostics Equipment Taiwan Limited, Grifols Diagnostics Solutions Inc, Grifols Engineering S.A., Grifols France S.A.R.L., Grifols India Healthcare Private Ltd, Grifols Innovation and New Technologies Limited, Grifols International S.A., Grifols Italia S.p.A, Grifols Japan K.K., Grifols Malaysia Sdn Bhd, Grifols Movaco S.A., Grifols México S.A. de C.V., Grifols Nordic AB, Grifols Pharmaceutical Technology (Shanghai) Co. Ltd., Grifols Polska Sp.z.o.o., Grifols Portugal Productos Farmacéuticos e Hospitalares Lda., Grifols Shared Services North America Inc., Grifols Switzerland AG, Grifols Therapeutics LLC., Grifols UK Ltd., Grifols USA LLC., Grifols Viajes S.A., Grifols Worldwide Operations Limited, Grifols Worldwide Operations Spain S.A., Grifols Worldwide Operations USA Inc., Grifols s.r.o., Gripdan Invest S.L, Haema AG, Instituto Grifols S.A., Interstate Blood Bank Inc., Kiro Grifols S.L, Kiro Robotics, Laboratorios Grifols S.A., Logística Grifols S.A. de C.V., Medion Diagnostics GmbH, Medion Grifols Diagnostic AG, PBS Acquisition Corp., Progenika Biopharma, Progenika Biopharma S.A., Squadron Reinsurance Designated Activity Company, Talecris Biotherapeutics, Talecris Plasma Resources Inc., and VCN Bioscience S.L..
Read More
How can I contact Grifols?

Grifols' mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The official website for the company is www.grifols.com. The biotechnology company can be reached via phone at (493) 571-0221, via email at inversores@grifols.com, or via fax at 34-93-571-0267.

This page (NASDAQ:GRFS) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -